Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
about
High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphomaComparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphomaHodgkin's lymphoma therapy: past, present, and future.High dose sequential chemotherapy and autologous stem cell transplantation in patients with relapsed/refractory lymphoma.The Management of Classical Hodgkin's Lymphoma: Past, Present, and FutureCurrent status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphomaPositron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy.Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Relapse in common lymphoma subtypes: salvage treatment options for follicular lymphoma, diffuse large cell lymphoma and Hodgkin disease.Stem cell transplantation in Hodgkin lymphoma.Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma.Optimal treatment for relapsing patients with Hodgkin lymphoma.Hodgkin's lymphoma: current treatment strategies and novel approaches.Management of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.Allogeneic transplantation for Hodgkin's lymphoma.The role of autologous transplantation in Hodgkin lymphoma.Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma.Management of children with high-risk Hodgkin lymphoma.Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancer.State of the art in the treatment of Hodgkin lymphoma.Update on salvage options in relapsed/refractory hodgkin lymphoma after autotransplant.Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma.Hematopoietic stem cell transplantation for Hodgkin's disease.Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma.High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease.Frequency, severity and risk factors for oral mucositis after BEAM conditioning and autologous peripheral blood stem cell transplantation: a single center analysis and review of the literature.Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma.Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: a SWOG and Blood & Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
P2860
Q24201885-B637338E-AC92-488D-A873-DE57A8B7CCA5Q33379431-379F508D-B9C2-4225-9283-9B3B33D4017FQ33411127-C6F9FF37-3337-4ED3-A058-95467B10C1BAQ33418817-0E106EDD-DDF1-459D-9923-2DCD09877B70Q34064220-1F921C3E-F6C5-47D2-906C-E35D7E169965Q34296914-02A06CAB-F8ED-491D-BB2B-8F3468D56097Q34570769-5E81DABB-8C11-4FE4-85BA-897216792BE3Q35038852-5AF23430-4AEF-4C65-A79D-682263764432Q35705317-5ECBA81A-0DA0-425A-B061-46719E35EA49Q36094726-D850B07E-57F8-4962-A58A-E60975D9147AQ36264723-EA1A28D0-C778-4DEC-A08C-9BE5B60D2BB5Q36411719-2E693F8C-8FD8-4661-B806-73DEF481CBBCQ36752029-1B775977-032F-4E0D-A7E4-851C290E334CQ37126593-E0F2F87D-3521-44A4-B9F4-4BA391E74543Q37178329-F5B6F4DE-DE68-4692-BB2F-06EFD6A0E591Q37316657-09D60C07-C5D6-40A5-AD4D-1C9EB68A2EE4Q37530611-98DA1520-E2D9-4F74-A85C-8A5DAE471883Q37713596-9E8D48A7-7314-4313-8197-70EB2BDD703BQ37810094-305E08DE-6944-4818-92D0-DAEEFB60AEF1Q37810114-0BBCFC78-A97C-45A2-BCA5-DC260DC68C67Q37816470-800959F9-4531-4166-A4A2-08530710087FQ37820685-F79EB2CF-F9F7-4B7E-BA04-C8E04F08654DQ37874982-E9FB9B45-86F2-4AA3-A761-C599BAEB8BBAQ37934952-E77361D9-52D6-4AD0-90C7-4336B8C285E3Q37970408-65D7CDB9-9142-4914-B29A-09FBDB596A44Q37996270-0CE3F6A1-46EF-49F5-A31C-AB2C74CF27DFQ38017914-1757FF1B-6A66-4418-93B3-9CCD08E4665AQ38227567-5843BA75-D139-4FFA-97DC-3BF8C6EF523FQ39019556-5874618D-75EC-45C3-9ECD-55BA4F0771DDQ39263090-858D1726-0B75-4631-9785-CF77336207DAQ39974781-855334A9-6AD1-48A4-8FF8-DDB51F42B285Q41902211-26494522-199F-4368-AF0C-7CEA2F7454E0Q43254042-4E627CDD-5688-4C49-B6AF-F5AEFD208F9AQ44780860-E8051006-1F49-47F5-9DEB-9A15869044B1Q45176571-AD1F934E-7E39-4721-9C7E-8E36D79CD0AEQ46600675-6B5A1ADC-5814-4D14-BD9E-E6BCC3383D43Q46909205-27FEF2CF-49BF-4B23-AE7A-8006914E27EEQ47130656-6F84E726-1C88-415A-ABDE-26AA09254353Q47229875-6A5C8248-78F3-46D0-831A-426FA99ACFDDQ51748489-A29A0D32-1331-4EE5-A6CE-4EB1CDD0CE8C
P2860
Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@ast
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@en
Cologne high-dose sequential c ...... n Hodgkin Lymphoma Study Group
@nl
type
label
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@ast
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@en
Cologne high-dose sequential c ...... n Hodgkin Lymphoma Study Group
@nl
prefLabel
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@ast
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@en
Cologne high-dose sequential c ...... n Hodgkin Lymphoma Study Group
@nl
P2093
P356
P1433
P1476
Cologne high-dose sequential c ...... n Lymphoma Study Group (GHSG).
@en
P2093
D K Hossfeld
H H Kirchner
J-P Glossmann
P304
P356
10.1093/ANNONC/MDI003
P577
2005-01-01T00:00:00Z